11th Annual Commercial Translation of Regenerative Medicine

11th Annual Commercial Translation of Regenerative Medicine

25-11-2013 - 26-11-2013 Charing Cross Hotel, London, United Kingdom

Growing year on year, the 11th Annual Commercial Translation of Regenerative Medicine Conference will delve into the current business challenges that are holding up commercialization.

Growing year on year, the 11th Annual Commercial Translation of Regenerative Medicine Conference will delve into the current business challenges that are holding up commercialization. This conference will help delegates see their potential through significant growth, considerable financial return and market access. Since regenerative medicine poses high risk to investors, the conference will also demonstrate the business strategies that are needed to mitigate risk from research, manufacturing to commercialization.

With new sources of revenue and novel technologies coming into place, the industry is keen on understanding how to capture and incorporate these into their business. Addressing the current regulatory landscape, delegates will also gain a holistic global oversight of the uncertainties the future may hold.

By attending this Commercial Translation of Regenerative Medicine Conference, delegates will benefit from understanding how to overcome funding, regulatory and manufacturing challenges for smooth transition into the market. Importantly, regenerative medicine is attracting the involvement of leading pharmaceutical players – this conference will look into their strategies and role in the industry. Come and share your experiences with leading decision makers to streamline your clinical success.

Attending this premier marcus evans event will enable you to:

  • Grasp the best business strategies to secure the future of your regenerative medicine products
  • Learn how new technologies and existing tools can be applied to commercial manufacturing
  • Update yourself on the regulatory progress and reimbursement consideration
  • Gain insight from the pharma perspective and design a road map to collaboratio
  • Leverage experiences from leading regenerative medicine companies and decision makers

Back to top